Cannabis Science Inc (fka CBIS)

[DouglasJH]

Seems that big pharma desperately wants a piece of the cannabiniod craze. I mentioned that I can find almost daily the race toward rescheduling. Today is also a good example.

Most pharmas know this report well: A drug discovery case history of ``delta-9-tetrahydrocannabinol, cannabidiol''

standardised pharmaceutical cannabinoids may constitute a useful addition to the pharmacotherapeutic armamentarium in chronic conditions insufficiently alleviated by existing drugs.

Today's news was this: Teva Pharmaceutical offers $6.8 billion for Cephalon

Teva offered Cephalon stockholders $81.50 a share, 12% more than Valeant's offer of $73.

U.S.-traded shares of Teva increased 3.4% to $47.27 on Monday. Cephalon stock rose 4% to $80.11. Valeant shares fell 5.8% to $49.58.

Chart 2 | Tevas strategic partners
 Proneuron
 Develogen (formerly Peptor)
 GamidaCell
 BiolineRx (incubator)
 VBL (Vascular Biogenics)
 Transpharma
 Proteologics
 NST (NeuroSurvival Technology)
 Curetech
 CBI (Clal Biotechnologies Industries, a life sciences investment fund)

Teva is the pharmaceutical firm that made rimovant which inhibits the bodies own endocannabinoids. NIH team reports breakthrough with new obesity drug July 26, 2010 I think this drug was pulled or never made to approval due to large number of suicides.






..